Mavacamten monotherapy in obstructive hypertrophic cardiomyopathy: an integrated analysis of phase 3 clinical trials.

This study assessed mavacamten monotherapy efficacy and safety in an integrated analysis of four phase 3 studies: EXPLORER-HCM, the EXPLORER cohort of MAVA-LTE, VALOR-HCM and EXPLORER-CN. Mavacamten monotherapy was associated with improvements in left ventricular outflow tract gradients and symptoms in patients with obstructive hypertrophic cardiomyopathy; descriptive comparisons with patients receiving mavacamten plus beta-blockers or calcium-channel blockers suggested broadly similar trends in efficacy and adverse event rates. Reductions in left ventricular ejection fraction from baseline to week 128 of ≤8.8% were observed across treatment groups.